Bone metastases (metastatic bone disease)
Many cancers settle in bone. They cause pain, fractures, high calcium and spinal cord compression, and spotting them early prevents most of the harm.
What it is
Cancer deposits in the skeleton that came from a tumour elsewhere. They are far commoner than primary bone cancer, arise mainly from breast, prostate, lung, kidney and thyroid cancer and myeloma, and favour the spine, pelvis, ribs, skull and proximal femur and humerus.
Who gets it
The skeleton is the third commonest site of metastasis after the lung and liver, and bone metastases are found in most patients with advanced breast or prostate cancer. In Colombia, breast and prostate cancer are among the commonest cancers, so bone metastases are frequent; radiotherapy, the main palliative treatment, is concentrated in the five largest cities, and some regions have no linear accelerator, so referral often means travel.
Causes
- Breast and prostate cancer: the two commonest sources; prostate is typically blastic, breast often mixed
- Lung, kidney and thyroid cancer: usually lytic; kidney and thyroid deposits are very vascular
- Multiple myeloma: purely lytic, punched-out lesions
- Less often melanoma, bladder, gastrointestinal cancers; in children neuroblastoma and sarcomas
Risk factors
- Advanced or high-risk breast, prostate, lung, kidney or thyroid cancer
- Multiple myeloma
- Lesions already present in the spine, where spread through the valveless vertebral venous plexus is common
- Long survival with metastatic disease, which gives more time for skeletal events
Pathophysiology
Tumour cells reach the red marrow, mostly through the blood and the vertebral venous plexus → they release signals (PTHrP and others) that raise RANKL and recruit osteoclasts, or signals that drive osteoblasts → osteoclasts dissolve bone and release growth factors that feed the tumour, a vicious cycle (lytic), or osteoblasts lay down disorganised woven bone (blastic) → the cortex thins and loses strength → pain, pathological fracture, collapse of a vertebra with pressure on the cord or roots, and calcium released into the blood.
Classification
- By pattern: lytic, blastic (sclerotic) or mixed
- By extent: solitary, oligometastatic (a few lesions), multiple, or bone plus visceral disease
- Skeletal-related events (SREs), the outcomes trials count: pathological fracture, radiotherapy to bone, surgery to bone and spinal cord compression (hypercalcaemia is sometimes added)
Symptoms and signs
- Bone pain, often the first sign: dull, worse at night, later constant
- Pain on weight bearing or with movement of a limb, a warning of impending fracture
- Sudden severe pain and deformity after minor force (pathological fracture)
- Back or neck pain, then limb weakness, numbness or bladder and bowel problems when the cord is compressed
- Thirst, polyuria, constipation, confusion and tiredness from hypercalcaemia
Diagnosis
- Clinical
- Suspected in a patient with known cancer and new bone pain, a pathological fracture or high calcium; less often bone is the first sign of an unknown primary. Examine the whole spine and a full neurological examination every time.
- Tests
- Serum calcium (corrected for albumin), alkaline phosphatase, kidney function and full blood count; tumour markers that fit the suspected primary (PSA, serum protein electrophoresis and free light chains for myeloma). Biopsy when there is no known primary, when it is the first metastasis, or when the result would change treatment; kidney and thyroid deposits can bleed heavily.
- Imaging
- Plain radiographs of painful bones, though a lesion shows only after much of the bone is lost; bone scintigraphy for blastic and mixed disease, which can miss purely lytic lesions such as myeloma; CT for cortical destruction and fracture risk; MRI of the whole spine for marrow disease and urgently when cord compression is suspected; PET-CT in selected cancers.
Differential diagnosis
- Osteoporotic vertebral fracture
- Primary bone tumour (osteosarcoma, chondrosarcoma, Ewing sarcoma)
- Osteomyelitis and spinal tuberculosis
- Paget disease of bone
- Degenerative disc and facet disease
- Hyperparathyroidism with brown tumours
Lytic, blastic or mixed: what the pattern tells you
| Pattern | Typical primaries | What the tumour does | Imaging clue | Clinical point |
|---|---|---|---|---|
| Lytic | Lung, kidney, thyroid, melanoma, gastrointestinal | Recruits osteoclasts to dissolve bone | Holes and cortical loss on X-ray or CT | Highest fracture risk; kidney and thyroid deposits bleed |
| Blastic (sclerotic) | Prostate, some breast and carcinoid | Drives osteoblasts to lay down disorganised bone | Dense white areas; hot on bone scan | Looks solid but is weak and painful |
| Mixed | Breast (often), lung | Both crews at once | Holes and dense areas together | Behaves like the lytic part for fracture risk |
| Myeloma | Plasma cell neoplasm | Suppresses osteoblasts and drives osteoclasts | Punched-out lesions; often normal bone scan | Use whole-body CT, MRI or PET, not a bone scan |
Goal of treatment
Relieve pain, prevent and treat fractures, cord compression and hypercalcaemia, keep the patient walking and independent, and treat the underlying cancer.
Treatment
- Acute
- Suspected spinal cord compression: urgent whole-spine MRI, a corticosteroid, and emergency radiotherapy or decompressive surgery the same day; see the malignant spinal cord compression page.
- Acute
- Hypercalcaemia: intravenous fluids, then a bisphosphonate or denosumab, as set by the guideline; see the hypercalcaemia of malignancy page.
- Medical
- Pain control along the analgesic ladder: paracetamol, an anti-inflammatory when kidneys and bleeding risk allow, and opioids for moderate to severe pain, with laxatives.
- Medical
- Bone-targeted agents (an intravenous bisphosphonate such as zoledronic acid, or denosumab) reduce skeletal-related events and bone pain. Before starting: a dental examination and any needed dental work, calcium and vitamin D, and a check of calcium and kidney function. Denosumab can cause severe hypocalcaemia, especially in kidney disease, and stopping it can be followed by vertebral fractures.
- Medical
- Treatment of the cancer itself, chosen by the oncology team: hormone therapy in breast and prostate cancer, chemotherapy, targeted therapy or immunotherapy.
- Procedure
- Palliative external beam radiotherapy for painful bone metastases: most patients get pain relief within weeks; short courses relieve uncomplicated bone pain about as well as longer ones, with the schedule set by the radiation oncologist. Stereotactic radiotherapy for selected spinal or oligometastatic lesions; bone-seeking radiopharmaceuticals for widespread painful blastic disease such as prostate cancer.
- Surgical
- Prophylactic fixation of an impending fracture (for example an intramedullary nail in the femur), fixation or joint replacement for a pathological fracture, followed by radiotherapy to the whole operated bone; vertebroplasty or kyphoplasty for painful vertebral collapse without cord compression.
- Rehabilitation
- Physiotherapy, walking aids and advice on safe loading of weakened bones, within a palliative care plan that starts early.
Complications
- Pathological fracture, most often of the proximal femur, vertebrae and humerus
- Spinal cord or cauda equina compression
- Hypercalcaemia of malignancy
- Marrow replacement with anaemia and other cytopenias
- Osteonecrosis of the jaw and hypocalcaemia from bone-targeted agents
Common traps
- A normal bone scan rules out bone metastases: the scan shows bone-forming reaction, so purely lytic lesions such as myeloma can be missed; use MRI, CT or PET-CT
- A normal X-ray of a painful bone rules out a metastasis: a lesion shows on plain film only after much of the bone has gone; image further if the pain persists
- Back pain in a cancer patient can wait for neurological signs: cord compression is treated before weakness appears, because walking ability at diagnosis predicts walking ability afterwards
- Fix the femur once it breaks: a painful lytic lesion with a high Mirels score is fixed before it fractures, which is safer and recovers faster
- Bisphosphonates and denosumab treat the cancer: they slow bone destruction and cut skeletal events, but the tumour needs its own treatment
Prognosis
Bone metastases are usually not curable, but survival varies widely by primary: patients with breast or prostate cancer and bone-only disease can live for years, while lung cancer with bone metastases has a short survival. Quality of life depends mostly on preventing skeletal events.
Prevention
- Bone-targeted agents in patients with established bone metastases to prevent skeletal events
- Early imaging of new bone pain in patients with cancer
- Teaching patients the warning signs of cord compression and when to seek urgent care
Test yourself
Think of the answer, then tap the question to see it.
Which four features make up the Mirels score for impending fracture of a long bone?
Site (upper limb, lower limb, peritrochanteric), pain (especially on weight bearing), lesion type (blastic, mixed, lytic) and size relative to the bone's diameter. A high score favours prophylactic fixation.
Why can a bone scan be normal in multiple myeloma?
Bone scintigraphy shows osteoblastic activity. Myeloma suppresses osteoblasts and causes purely lytic lesions, so whole-body CT, MRI or PET is used instead.
What must be done before starting zoledronic acid or denosumab for bone metastases, and why?
A dental examination and any needed dental work, because both can cause osteonecrosis of the jaw; also check calcium and kidney function and give calcium and vitamin D.
A 64-year-old man with prostate cancer has new thoracic back pain at night and stiff legs. What is the next step?
Treat it as suspected cord compression: urgent whole-spine MRI, a corticosteroid and same-day referral for radiotherapy or surgery.
Which skeletal-related events do trials count in bone metastases?
Pathological fracture, radiotherapy to bone, surgery to bone and spinal cord compression; hypercalcaemia is sometimes included.
Connections
Educational information, not medical advice. For any symptom, see a health professional.
Sources: Bone Metastasis (StatPearls (NCBI Bookshelf), 2023); Palliative Radiation Therapy For Bone Metastases (StatPearls (NCBI Bookshelf), 2024); Bone Metastases (American Cancer Society, 2026); Advancements in Assessing Pathological Fracture Risk: News on Mirels' Score (Cancers (Basel), PubMed Central, 2025); Denosumab Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); Estimation of the Need for Radiation Therapy Services According to the Incidence of Cancer in Colombia to 2035 (Advances in Radiation Oncology, PubMed Central, 2021).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.

